MMDA was described by
Alexander Shulgin in his book PiHKAL. Shulgin lists the dosage range of MMDA as 100–250 mg. The first effects appear within 30–60 minutes following
oral administration. MMDA produces
euphoria and loving warmth, and attenuates feelings such as
anxiety and
loneliness. MMDA also produces closed eye
visuals, a state of
drowsiness,
muscle relaxation, and time distortion.
Side effects include moderate
mydriasis,
dizziness, sensations of
heat or cold, and
trembling. The
imagery is generally realistic, and often related to everyday
perception of people, landscapes, or objects. The effects of MMDA usually reach a
peak during the first hour following the initial effects, and begin to wane during the second hour, and usually completely disappear by the end of the fifth hour.
Psychotherapeutic actions
In his 1973 book, The Healing Journey,
Claudio Naranjo explored the
psychotherapeutic potential of MMDA. Like MDA, he found that MMDA facilitates
communication and suggested it has potential applications in
psychotherapy. Worldwide as of 2005[update], MMDA has not been approved for any human applications.
MMDA is classified as a
Schedule 1 substance in the United States, and is similarly controlled in other parts of the world. It is important to note that MMDA remains illegal, however it is classified differently than the illegality of MDMA.[clarification needed]
MMDA is considered a Schedule 9 prohibited substance in Australia under the
Poisons Standard (October 2015).[5] A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.[5]
MMDA was described by
Alexander Shulgin in his book PiHKAL. Shulgin lists the dosage range of MMDA as 100–250 mg. The first effects appear within 30–60 minutes following
oral administration. MMDA produces
euphoria and loving warmth, and attenuates feelings such as
anxiety and
loneliness. MMDA also produces closed eye
visuals, a state of
drowsiness,
muscle relaxation, and time distortion.
Side effects include moderate
mydriasis,
dizziness, sensations of
heat or cold, and
trembling. The
imagery is generally realistic, and often related to everyday
perception of people, landscapes, or objects. The effects of MMDA usually reach a
peak during the first hour following the initial effects, and begin to wane during the second hour, and usually completely disappear by the end of the fifth hour.
Psychotherapeutic actions
In his 1973 book, The Healing Journey,
Claudio Naranjo explored the
psychotherapeutic potential of MMDA. Like MDA, he found that MMDA facilitates
communication and suggested it has potential applications in
psychotherapy. Worldwide as of 2005[update], MMDA has not been approved for any human applications.
MMDA is classified as a
Schedule 1 substance in the United States, and is similarly controlled in other parts of the world. It is important to note that MMDA remains illegal, however it is classified differently than the illegality of MDMA.[clarification needed]
MMDA is considered a Schedule 9 prohibited substance in Australia under the
Poisons Standard (October 2015).[5] A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.[5]